260
- Feltelius N, et al. Results from a nationwide postmarketing cohort study of patients in Sweden
treated with etanercept. Ann Rheum Dis. 2005;64(2):246–52. - Adamson R, et al. Fatal acute necrotizing eosinophilic myocarditis temporally related to use of
adalimumab in a patient with relapsing polychondritis. J Clin Rheumatol. 2013;19(7):386–9. - Balakumar P, Singh M. Anti-tumour necrosis factor-alpha therapy in heart failure: future
directions. Basic Clin Pharmacol Toxicol. 2006;99(6):391–7. - Kurrelmeyer KM, et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte
against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc
Natl Acad Sci U S A. 2000;97(10):5456–61. - Sugamori T, et al. Increased nitric oxide in proportion to the severity of heart failure in
patients with dilated cardiomyopathy: close correlation of tumor necrosis factor-alpha with
systemic and local production of nitric oxide. Circ J. 2002;66(7):627–32. - Mann DL. Tumor necrosis factor-induced signal transduction and left ventricular remodel-
ing. J Card Fail. 2002;8(6 Suppl):S379–86. - Sinagra E, et al. Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflam-
matory diseases. Eur J Intern Med. 2013;24(5):385–92.
U. Wong and R.K. Cross